1: Malhi H, Homad LJ, Wan YH, Poudel B, Fiala B, Borst AJ, Wang JY, Walkey C,
Price J, Wall A, Singh S, Moodie Z, Carter L, Handa S, Correnti CE, Stoddard BL,
Veesler D, Pancera M, Olson J, King NP, McGuire AT. Immunization with a self-
assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice
against lethal viral challenge. Cell Rep Med. 2022 Jun 21;3(6):100658. doi:
10.1016/j.xcrm.2022.100658. Epub 2022 Jun 14. PMID: 35705092; PMCID: PMC9245003.

2: Gray GE, Bekker LG, Laher F, Malahleha M, Allen M, Moodie Z, Grunenberg N,
Huang Y, Grove D, Prigmore B, Kee JJ, Benkeser D, Hural J, Innes C, Lazarus E,
Meintjes G, Naicker N, Kalonji D, Nchabeleng M, Sebe M, Singh N, Kotze P, Kassim
S, Dubula T, Naicker V, Brumskine W, Ncayiya CN, Ward AM, Garrett N, Kistnasami
G, Gaffoor Z, Selepe P, Makhoba PB, Mathebula MP, Mda P, Adonis T, Mapetla KS,
Modibedi B, Philip T, Kobane G, Bentley C, Ramirez S, Takuva S, Jones M,
Sikhosana M, Atujuna M, Andrasik M, Hejazi NS, Puren A, Wiesner L, Phogat S,
Diaz Granados C, Koutsoukos M, Van Der Meeren O, Barnett SW, Kanesa-Thasan N,
Kublin JG, McElrath MJ, Gilbert PB, Janes H, Corey L; HVTN 702 Study Team.
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. N
Engl J Med. 2021 Mar 25;384(12):1089-1100. doi: 10.1056/NEJMoa2031499. PMID:
33761206; PMCID: PMC7888373.

3: Cohen KW, Linderman SL, Moodie Z, Czartoski J, Lai L, Mantus G, Norwood C,
Nyhoff LE, Edara VV, Floyd K, De Rosa SC, Ahmed H, Whaley R, Patel SN, Prigmore
B, Lemos MP, Davis CW, Furth S, O'Keefe JB, Gharpure MP, Gunisetty S, Stephens
K, Antia R, Zarnitsyna VI, Stephens DS, Edupuganti S, Rouphael N, Anderson EJ,
Mehta AK, Wrammert J, Suthar MS, Ahmed R, McElrath MJ. Longitudinal analysis
shows durable and broad immune memory after SARS-CoV-2 infection with persisting
antibody responses and memory B and T cells. Cell Rep Med. 2021 Jul
20;2(7):100354. doi: 10.1016/j.xcrm.2021.100354. Epub 2021 Jul 3. PMID:
34250512; PMCID: PMC8253687.

4: Balle C, Konstantinus IN, Jaumdally SZ, Havyarimana E, Lennard K, Esra R,
Barnabas SL, Happel AU, Moodie Z, Gill K, Pidwell T, Karaoz U, Brodie E, Maseko
V, Gamieldien H, Bosinger SE, Myer L, Bekker LG, Passmore JS, Jaspan HB.
Hormonal contraception alters vaginal microbiota and cytokines in South African
adolescents in a randomized trial. Nat Commun. 2020 Nov 4;11(1):5578. doi:
10.1038/s41467-020-19382-9. PMID: 33149114; PMCID: PMC7643181.

5: Stamatatos L, Czartoski J, Wan YH, Homad LJ, Rubin V, Glantz H, Neradilek M,
Seydoux E, Jennewein MF, MacCamy AJ, Feng J, Mize G, De Rosa SC, Finzi A, Lemos
MP, Cohen KW, Moodie Z, McElrath MJ, McGuire AT. mRNA vaccination boosts cross-
variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021
Mar 25;372(6549):1413–8. doi: 10.1126/science.abg9175. Epub ahead of print.
PMID: 33766944; PMCID: PMC8139425.

6: Moodie Z, Janes H, Huang Y. New clinical trial designs for HIV vaccine
evaluation. Curr Opin HIV AIDS. 2013 Sep;8(5):437-42. doi:
10.1097/COH.0b013e328363d46a. PMID: 23872613; PMCID: PMC3872029.

7: Talla A, Vasaikar SV, Szeto GL, Lemos MP, Czartoski JL, MacMillan H, Moodie
Z, Cohen KW, Fleming LB, Thomson Z, Okada L, Becker LA, Coffey EM, De Rosa SC,
Newell EW, Skene PJ, Li X, Bumol TF, Juliana McElrath M, Torgerson TR.
Persistent serum protein signatures define an inflammatory subcategory of long
COVID. Nat Commun. 2023 Jun 9;14(1):3417. doi: 10.1038/s41467-023-38682-4. PMID:
37296110; PMCID: PMC10252177.

8: Talla A, Vasaikar SV, Lemos MP, Moodie Z, Lee Pebworth MP, Henderson KE,
Cohen KW, Czartoski JL, Lai L, Suthar MS, Heubeck AT, Genge PC, Roll CR, Weiss
M, Reading J, Kondza N, MacMillan H, Fong OC, Thomson ZJ, Graybuck LT, Okada LY,
Newell EW, Coffey EM, Meijer P, Becker LA, De Rosa SC, Skene PJ, Torgerson TR,
Li XJ, Szeto GL, McElrath MJ, Bumol TF. Longitudinal immune dynamics of mild
COVID-19 define signatures of recovery and persistence. bioRxiv [Preprint]. 2021
Aug 19:2021.05.26.442666. doi: 10.1101/2021.05.26.442666. PMID: 34075380; PMCID:
PMC8168393.

9: Stamatatos L, Czartoski J, Wan YH, Homad LJ, Rubin V, Glantz H, Neradilek M,
Seydoux E, Jennewein MF, MacCamy AJ, Feng J, Mize G, De Rosa SC, Finzi A, Lemos
MP, Cohen KW, Moodie Z, McElrath MJ, McGuire AT. A single mRNA immunization
boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.
medRxiv [Preprint]. 2021 Mar 10:2021.02.05.21251182. doi:
10.1101/2021.02.05.21251182. Update in: Science. 2021 Mar 25;: PMID: 33758873;
PMCID: PMC7987032.

10: Fischinger S, Cizmeci D, Deng D, Grant SP, Frahm N, McElrath J, Fuchs J,
Bart PA, Pantaleo G, Keefer M, O Hahn W, Rouphael N, Churchyard G, Moodie Z,
Donastorg Y, Streeck H, Alter G. Sequence and vector shapes vaccine induced
antibody effector functions in HIV vaccine trials. PLoS Pathog. 2021 Nov
29;17(11):e1010016. doi: 10.1371/journal.ppat.1010016. PMID: 34843602; PMCID:
PMC8659322.

11: Dintwe OB, De Rosa SC, Huang Y, Flach BS, Manso B, Carter D, Omar FL,
Schwedhelm KV, Yu C, Lu H, Morris D, Kee JJ, Voillet V, Stirewalt M, Hural J,
Moodie Z, Frahm N, Cohen KW, McElrath MJ, Andersen-Nissen E. Achieving
intracellular cytokine staining assay concordance on two continents to assess
HIV vaccine-induced T-cell responses. J Leukoc Biol. 2022 Nov;112(5):1167-1181.
doi: 10.1002/JLB.5MA0522-668R. Epub 2022 Jul 22. PMID: 35866359; PMCID:
PMC10229754.

12: Malahleha M, Laher F, Dilraj A, Smith P, Gray GE, Grove D, Odhiambo JA,
Andrasik MP, Grunenberg NA, Moodie Z, Huang Y, Borate BR, Gillespie KM, Allen M,
Atujuna M, Singh N, Kalonji D, Meintjes G, Kotze P, Bekker LG, Janes H. Risk
Factors Associated with HIV Acquisition in Males Participating in HIV Vaccine
Efficacy Trials in South Africa. AIDS Behav. 2023 Sep;27(9):3027-3037. doi:
10.1007/s10461-023-04025-z. Epub 2023 Mar 16. PMID: 36929319; PMCID:
PMC10386918.

13: Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, Savarino
S, Zambrano B, Moureau A, Khromava A, Moodie Z, Westling T, Mascareñas C, Frago
C, Cortés M, Chansinghakul D, Noriega F, Bouckenooghe A, Chen J, Ng SP, Gilbert
PB, Gurunathan S, DiazGranados CA. Effect of Dengue Serostatus on Dengue Vaccine
Safety and Efficacy. N Engl J Med. 2018 Jul 26;379(4):327-340. doi:
10.1056/NEJMoa1800820. Epub 2018 Jun 13. PMID: 29897841.

14: Mashingaidze R, Moodie Z, Allen M, Bekker LG, Grove D, Grunenberg N, Huang
Y, Janes HE, Lazarus EM, Malahleha M, Nchabeleng M, Laher F. Sexually
transmitted infections amongst men who have sex with men (MSM) in South Africa.
PLOS Glob Public Health. 2023 Apr 5;3(4):e0001782. doi:
10.1371/journal.pgph.0001782. PMID: 37018240; PMCID: PMC10075439.

15: Qi L, Sun Y, Juraska M, Moodie Z, Magaret CA, Heng F, Carpp LN, Gilbert PB.
Neutralizing antibody correlates of sequence specific dengue disease in a
tetravalent dengue vaccine efficacy trial in Asia. Vaccine. 2022 Sep
29;40(41):5912-5923. doi: 10.1016/j.vaccine.2022.08.055. Epub 2022 Sep 5. PMID:
36068106; PMCID: PMC9881745.

16: Moodie Z, Price L, Janetzki S, Britten CM. Response determination criteria
for ELISPOT: toward a standard that can be applied across laboratories. Methods
Mol Biol. 2012;792:185-96. doi: 10.1007/978-1-61779-325-7_15. PMID: 21956511.

17: Cohen KW, Linderman SL, Moodie Z, Czartoski J, Lai L, Mantus G, Norwood C,
Nyhoff LE, Edara VV, Floyd K, De Rosa SC, Ahmed H, Whaley R, Patel SN, Prigmore
B, Lemos MP, Davis CW, Furth S, O'Keefe J, Gharpure MP, Gunisetty S, Stephens
KA, Antia R, Zarnitsyna VI, Stephens DS, Edupuganti S, Rouphael N, Anderson EJ,
Mehta AK, Wrammert J, Suthar MS, Ahmed R, McElrath MJ. Longitudinal analysis
shows durable and broad immune memory after SARS-CoV-2 infection with persisting
antibody responses and memory B and T cells. medRxiv [Preprint]. 2021 Jun
18:2021.04.19.21255739. doi: 10.1101/2021.04.19.21255739. Update in: Cell Rep
Med. 2021 Jul 20;2(7):100354. PMID: 33948610; PMCID: PMC8095229.

18: Ditse Z, Mkhize NN, Yin M, Keefer M, Montefiori DC, Tomaras GD, Churchyard
G, Mayer KH, Karuna S, Morgan C, Bekker LG, Mlisana K, Gray G, Moodie Z, Gilbert
P, Moore PL, Williamson C, Morris L. Effect of HIV Envelope Vaccination on the
Subsequent Antibody Response to HIV Infection. mSphere. 2020 Jan
29;5(1):e00738-19. doi: 10.1128/mSphere.00738-19. PMID: 31996422; PMCID:
PMC6992371.

19: Moodie Z, Juraska M, Huang Y, Zhuang Y, Fong Y, Carpp LN, Self SG,
Chambonneau L, Small R, Jackson N, Noriega F, Gilbert PB. Neutralizing Antibody
Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and
Latin America. J Infect Dis. 2018 Feb 14;217(5):742-753. doi:
10.1093/infdis/jix609. PMID: 29194547; PMCID: PMC5854020.

20: Moodie Z, Dintwe O, Sawant S, Grove D, Huang Y, Janes H, Heptinstall J, Omar
FL, Cohen K, De Rosa SC, Zhang L, Yates NL, Sarzotti-Kelsoe M, Seaton KE, Laher
F, Bekker LG, Malahleha M, Innes C, Kassim S, Naicker N, Govender V, Sebe M,
Singh N, Kotze P, Lazarus E, Nchabeleng M, Ward AM, Brumskine W, Dubula T,
Randhawa AK, Grunenberg N, Hural J, Kee JJ, Benkeser D, Jin Y, Carpp LN, Allen
M, D'Souza P, Tartaglia J, DiazGranados CA, Koutsoukos M, Gilbert PB, Kublin JG,
Corey L, Andersen-Nissen E, Gray GE, Tomaras GD, McElrath MJ. Analysis of the
HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa
Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. J
Infect Dis. 2022 Aug 24;226(2):246-257. doi: 10.1093/infdis/jiac260. PMID:
35758878; PMCID: PMC9890908.

21: Thomas R, Chansinghakul D, Limkittikul K, Gilbert PB, Hattasingh W, Moodie
Z, Shangguan S, Frago C, Dulyachai W, Li SS, Jarman RG, Geretz A, Bouckenooghe
A, Sabchareon A, Juraska M, Ehrenberg P, Michael NL, Bailleux F, Bryant C,
Gurunathan S. Associations of human leukocyte antigen with neutralizing antibody
titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand. Hum
Immunol. 2022 Jan;83(1):53-60. doi: 10.1016/j.humimm.2021.09.006. Epub 2021 Oct
8. PMID: 34635391.

22: Huang Y, Williamson BD, Moodie Z, Carpp LN, Chambonneau L, DiazGranados CA,
Gilbert PB. Analysis of Neutralizing Antibodies as a Correlate of Instantaneous
Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy
Trials. J Infect Dis. 2022 Jan 18;225(2):332-340. doi: 10.1093/infdis/jiab342.
PMID: 34174082; PMCID: PMC8915240.

23: Fisher L, Zinter M, Stanfield-Oakley S, Carpp LN, Edwards RW, Denny T,
Moodie Z, Laher F, Bekker LG, McElrath MJ, Gilbert PB, Corey L, Tomaras G,
Pollara J, Ferrari G. Vaccine-Induced Antibodies Mediate Higher Antibody-
Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural
Killer Effector Cells. Front Immunol. 2019 Nov 27;10:2741. doi:
10.3389/fimmu.2019.02741. PMID: 31827470; PMCID: PMC6890556.

24: Healy SA, Murphy SC, Hume JCC, Shelton L, Kuntz S, Van Voorhis WC, Moodie Z,
Metch B, Wang R, Silver-Brace T, Fishbaugher M, Kennedy M, Finney OC, Chaturvedi
R, Marcsisin SR, Hobbs CV, Warner-Lubin M, Talley AK, Wong-Madden S, Stuart K,
Wald A, Kappe SH, Kublin JG, Duffy PE. Chemoprophylaxis Vaccination: Phase I
Study to Explore Stage-specific Immunity to Plasmodium falciparum in US Adults.
Clin Infect Dis. 2020 Sep 12;71(6):1481-1490. doi: 10.1093/cid/ciz1010. PMID:
31621832; PMCID: PMC7486848.

25: Zhao LP, Fiore-Gartland A, Carpp LN, Cohen KW, Rouphael N, Fleurs L, Dintwe
O, Zhao M, Moodie Z, Fong Y, Garrett N, Huang Y, Innes C, Janes HE, Lazarus E,
Michael NL, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, De Rosa SC,
Corey L, Gray GE, Seaton KE, Yates NL, McElrath MJ, Frahm N, Tomaras GD, Gilbert
PB. Landscapes of binding antibody and T-cell responses to pox-protein HIV
vaccines in Thais and South Africans. PLoS One. 2020 Jan 30;15(1):e0226803. doi:
10.1371/journal.pone.0226803. PMID: 31999736; PMCID: PMC6992005.

26: Laher F, Malahleha M, Ramirez S, Brumskine W, Otwombe K, Moodie Z, Allen M.
Data quality in an HIV vaccine efficacy clinical trial in South Africa: through
natural disasters and with discipline. BMC Med Res Methodol. 2023 Jun
24;23(1):147. doi: 10.1186/s12874-023-01967-9. PMID: 37355583; PMCID:
PMC10290289.

27: Ritchie AJ, Campion SL, Kopycinski J, Moodie Z, Wang ZM, Pandya K, Moore S,
Liu MK, Brackenridge S, Kuldanek K, Legg K, Cohen MS, Delwart EL, Haynes BF,
Fidler S, McMichael AJ, Goonetilleke N. Differences in HIV-specific T cell
responses between HIV-exposed and -unexposed HIV-seronegative individuals. J
Virol. 2011 Apr;85(7):3507-16. doi: 10.1128/JVI.02444-10. Epub 2011 Jan 26.
PMID: 21270166; PMCID: PMC3067859.

28: Huang Y, Moodie Z, Juraska M, Fong Y, Carpp LN, Chambonneau L, Coronel DL,
Dayan GH, DiazGranados CA, Gilbert PB. Immunobridging efficacy of a tetravalent
dengue vaccine against dengue and against hospitalized dengue from
children/adolescents to adults in highly endemic countries. Trans R Soc Trop Med
Hyg. 2021 Jul 1;115(7):750-763. doi: 10.1093/trstmh/traa154. PMID: 33369671;
PMCID: PMC8245293.

29: Shen X, Laher F, Moodie Z, McMillan AS, Spreng RL, Gilbert PB, Huang Y,
Yates NL, Grunenberg N, Juliana McElrath M, Allen M, Pensiero M, Mehra VL, Der
Meeren OV, Barnett SW, Phogat S, Gray GE, Bekker LG, Corey L, Tomaras GD. HIV-1
Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus
Prime gp120 Boost Vaccine Regimens. Sci Rep. 2020 Feb 7;10(1):2093. doi:
10.1038/s41598-020-57491-z. PMID: 32034163; PMCID: PMC7005751.

30: Dayan GH, Langevin E, Gilbert PB, Wu Y, Moodie Z, Forrat R, Price B, Frago
C, Bouckenooghe A, Cortes M, Noriega F, DiazGranados CA. Assessment of the long-
term efficacy of a dengue vaccine against symptomatic, virologically-confirmed
dengue disease by baseline dengue serostatus. Vaccine. 2020 Apr
23;38(19):3531-3536. doi: 10.1016/j.vaccine.2020.03.029. Epub 2020 Mar 20. PMID:
32204943.

31: Moodie Z, Rossini AJ, Hudgens MG, Gilbert PB, Self SG, Russell ND.
Statistical evaluation of HIV vaccines in early clinical trials. Contemp Clin
Trials. 2006 Apr;27(2):147-60. doi: 10.1016/j.cct.2005.11.008. Epub 2006 Jan 19.
PMID: 16426900.

32: Pasin C, Halloran ME, Gilbert PB, Langevin E, Ochiai RL, Pitisuttithum P,
Capeding MR, Carrasquilla G, Frago C, Cortés M, Chambonneau L, Moodie Z. Periods
of high dengue transmission defined by rainfall do not impact efficacy of dengue
vaccine in regions of endemic disease. PLoS One. 2018 Dec 13;13(12):e0207878.
doi: 10.1371/journal.pone.0207878. PMID: 30543657; PMCID: PMC6292612.

33: Dinges WL, Richardt J, Friedrich D, Jalbert E, Liu Y, Stevens CE, Maenza J,
Collier AC, Geraghty DE, Smith J, Moodie Z, Mullins JI, McElrath MJ, Horton H.
Virus-specific CD8+ T-cell responses better define HIV disease progression than
HLA genotype. J Virol. 2010 May;84(9):4461-8. doi: 10.1128/JVI.02438-09. Epub
2010 Feb 10. PMID: 20147397; PMCID: PMC2863751.

34: Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch
B, Janes H, Keefer MC, Churchyard G, Robb ML, Fast PE, Duerr A, McElrath MJ,
Corey L, Mascola JR, Graham BS, Sobieszczyk ME, Kublin JG, Robertson M, Hammer
SM, Gray GE, Buchbinder SP, Gilbert PB. Effect of rAd5-Vector HIV-1 Preventive
Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized
Trials. PLoS One. 2015 Sep 2;10(9):e0136626. doi: 10.1371/journal.pone.0136626.
PMID: 26332672; PMCID: PMC4558095.

35: McKinnon LR, Hughes SM, De Rosa SC, Martinson JA, Plants J, Brady KE, Gumbi
PP, Adams DJ, Vojtech L, Galloway CG, Fialkow M, Lentz G, Gao D, Shu Z, Nyanga
B, Izulla P, Kimani J, Kimwaki S, Bere A, Moodie Z, Landay AL, Passmore JA, Kaul
R, Novak RM, McElrath MJ, Hladik F. Optimizing viable leukocyte sampling from
the female genital tract for clinical trials: an international multi-site study.
PLoS One. 2014 Jan 15;9(1):e85675. doi: 10.1371/journal.pone.0085675. PMID:
24454917; PMCID: PMC3893217.

36: Gilbert PB, Huang Y, Juraska M, Moodie Z, Fong Y, Luedtke A, Zhuang Y, Shao
J, Carpp LN, Jackson N, Chambonneau L, Bouckenooghe A, Zambrano B, Frago C,
Pallardy S, Noriega F. Bridging Efficacy of a Tetravalent Dengue Vaccine from
Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing
Antibody Response. Am J Trop Med Hyg. 2019 Jul;101(1):164-179. doi:
10.4269/ajtmh.18-0534. PMID: 31115304; PMCID: PMC6609170.

37: Carpp LN, Fong Y, Bonaparte M, Moodie Z, Juraska M, Huang Y, Price B, Zhuang
Y, Shao J, Zheng L, Chambonneau L, Small R, Sridhar S, DiazGranados CA, Gilbert
PB. Microneutralization assay titer correlates analysis in two phase 3 trials of
the CYD-TDV tetravalent dengue vaccine in Asia and Latin America. PLoS One. 2020
Jun 15;15(6):e0234236. doi: 10.1371/journal.pone.0234236. PMID: 32542024; PMCID:
PMC7295445.

38: Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, Nchabeleng
M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C, Mathebula M, Allen M, McElrath
MJ, Robertson M, Kublin J, Corey L; HVTN 503/Phambili study team. Recombinant
adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term
follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis. 2014
May;14(5):388-96. doi: 10.1016/S1473-3099(14)70020-9. Epub 2014 Feb 20. PMID:
24560541; PMCID: PMC4174314.

39: Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM,
Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ, Keefer MC, Baden LR, Swann
EM, Grant S, Ahmed H, Li F, Hertz T, Self SG, Friedrich D, Frahm N, Liao HX,
Montefiori DC, Tomaras GD, McElrath MJ, Hural J, Graham BS, Jin X; HVTN 083
Study Group and the NIAID HVTN. Vaccination With Heterologous HIV-1 Envelope
Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to
Conserved Regions: HVTN 083. J Infect Dis. 2016 Feb 15;213(4):541-50. doi:
10.1093/infdis/jiv496. Epub 2015 Oct 15. PMID: 26475930; PMCID: PMC4721914.

40: Moodie Z, Metch B, Bekker LG, Churchyard G, Nchabeleng M, Mlisana K, Laher
F, Roux S, Mngadi K, Innes C, Mathebula M, Allen M, Bentley C, Gilbert PB,
Robertson M, Kublin J, Corey L, Gray GE. Continued Follow-Up of Phambili Phase
2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1
Acquisition among Vaccinated Men. PLoS One. 2015 Sep 14;10(9):e0137666. doi:
10.1371/journal.pone.0137666. PMID: 26368824; PMCID: PMC4569275.

41: Bekker LG, Moodie Z, Grunenberg N, Laher F, Tomaras GD, Cohen KW, Allen M,
Malahleha M, Mngadi K, Daniels B, Innes C, Bentley C, Frahm N, Morris DE, Morris
L, Mkhize NN, Montefiori DC, Sarzotti-Kelsoe M, Grant S, Yu C, Mehra VL,
Pensiero MN, Phogat S, DiazGranados CA, Barnett SW, Kanesa-Thasan N, Koutsoukos
M, Michael NL, Robb ML, Kublin JG, Gilbert PB, Corey L, Gray GE, McElrath MJ;
HVTN 100 Protocol Team. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59
HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2
trial. Lancet HIV. 2018 Jul;5(7):e366-e378. doi: 10.1016/S2352-3018(18)30071-7.
Epub 2018 Jun 18. PMID: 29898870; PMCID: PMC6028742.

42: Moodie Z, Huang Y, Gu L, Hural J, Self SG. Statistical positivity criteria
for the analysis of ELISpot assay data in HIV-1 vaccine trials. J Immunol
Methods. 2006 Aug 31;315(1-2):121-32. doi: 10.1016/j.jim.2006.07.015. Epub 2006
Aug 15. PMID: 16959262.

43: McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD,
Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG,
Corey L, Shiver JW, Casimiro DR; Step Study Protocol Team. HIV-1 vaccine-induced
immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008
Nov 29;372(9653):1894-1905. doi: 10.1016/S0140-6736(08)61592-5. Epub 2008 Nov
13. PMID: 19012957; PMCID: PMC2774110.

44: Ritchie AJ, Kuldanek K, Moodie Z, Wang ZM, Fox J, Nsubuga RN, Legg K,
Birabwa EF, Kaleebu P, McMichael AJ, Watera C, Goonetilleke N, Fidler S.
Comparison of sexual behavior and HIV risk between two HIV-1 serodiscordant
couple cohorts: the CHAVI 002 study. PLoS One. 2012;7(5):e37727. doi:
10.1371/journal.pone.0037727. Epub 2012 May 22. PMID: 22629447; PMCID:
PMC3358272.

45: Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, Mlisana
K, Metch B, de Bruyn G, Latka MH, Roux S, Mathebula M, Naicker N, Ducar C,
Carter DK, Puren A, Eaton N, McElrath MJ, Robertson M, Corey L, Kublin JG; HVTN
503/Phambili study team. Safety and efficacy of the HVTN 503/Phambili study of a
clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised,
placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011
Jul;11(7):507-15. doi: 10.1016/S1473-3099(11)70098-6. Epub 2011 May 11. Erratum
in: Lancet Infect Dis. 2011 Jul;11(7):495. PMID: 21570355; PMCID: PMC3417349.

46: Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME, Koup RA,
Roederer M, Bailer RT, Moodie Z, Gu L, Yan L, Graham BS; VRC 201/203 Study Team.
Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against
Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals. Vaccine.
2007 Feb 9;25(8):1513-25. doi: 10.1016/j.vaccine.2006.10.047. Epub 2006 Nov 7.
PMID: 17126963; PMCID: PMC1892755.

47: Fiore-Gartland A, Manso BA, Friedrich DP, Gabriel EE, Finak G, Moodie Z,
Hertz T, De Rosa SC, Frahm N, Gilbert PB, McElrath MJ. Pooled-Peptide Epitope
Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods
for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine
Efficacy Trials. PLoS One. 2016 Feb 10;11(2):e0147812. doi:
10.1371/journal.pone.0147812. PMID: 26863315; PMCID: PMC4749288.

48: Lhomme E, Richert L, Moodie Z, Pasin C, Kalams SA, Morgan C, Self S, De Rosa
SC, Thiébaut R. Early CD4+ T Cell Responses Are Associated with Subsequent CD8+
T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy.
PLoS One. 2016 Apr 28;11(4):e0152952. doi: 10.1371/journal.pone.0152952. PMID:
27124598; PMCID: PMC4849671.

49: Kong WP, Huang Y, Yang ZY, Chakrabarti BK, Moodie Z, Nabel GJ.
Immunogenicity of multiple gene and clade human immunodeficiency virus type 1
DNA vaccines. J Virol. 2003 Dec;77(23):12764-72. doi:
10.1128/jvi.77.23.12764-12772.2003. PMID: 14610198; PMCID: PMC262562.

50: Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ. Overcoming immunity
to a viral vaccine by DNA priming before vector boosting. J Virol. 2003
Jan;77(1):799-803. doi: 10.1128/jvi.77.1.799-803.2003. PMID: 12477888; PMCID:
PMC140625.

51: Huang Y, Duerr A, Frahm N, Zhang L, Moodie Z, De Rosa S, McElrath MJ,
Gilbert PB. Immune-correlates analysis of an HIV-1 vaccine efficacy trial
reveals an association of nonspecific interferon-γ secretion with increased
HIV-1 infection risk: a cohort-based modeling study. PLoS One. 2014 Nov
4;9(11):e108631. doi: 10.1371/journal.pone.0108631. PMID: 25369172; PMCID:
PMC4219669.

52: Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Martin JE,
McCluskey MM, Chakrabarti BK, Lamoreaux L, Andrews CA, Gomez PL, Mascola JR,
Nabel GJ; Vaccine Research Center 004 Study Team. Phase 1 safety and
immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect
Dis. 2006 Dec 15;194(12):1650-60. doi: 10.1086/509259. Epub 2006 Nov 8. PMID:
17109336; PMCID: PMC2428069.

53: Pala P, Serwanga J, Watera C, Ritchie AJ, Moodie Z, Wang M, Goonetilleke N,
Birabwa E, Hughes P, Senkaali D, Nakiboneka R, Grosskurth H, Haynes B, McMichael
A, Kaleebu P; Center for HIV/AIDS Vaccine Immunology. Quantitative and
qualitative differences in the T cell response to HIV in uninfected Ugandans
exposed or unexposed to HIV-infected partners. J Virol. 2013 Aug;87(16):9053-63.
doi: 10.1128/JVI.00721-13. Epub 2013 Jun 12. PMID: 23760253; PMCID: PMC3754030.

54: Peiperl L, Morgan C, Moodie Z, Li H, Russell N, Graham BS, Tomaras GD, De
Rosa SC, McElrath MJ; NIAID HIV Vaccine Trials Network. Safety and
immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in
Ad5-seronegative persons: a randomized clinical trial (HVTN 054). PLoS One. 2010
Oct 27;5(10):e13579. doi: 10.1371/journal.pone.0013579. PMID: 21048953; PMCID:
PMC2965084.

55: Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D,
Gray G, Bekker LG, McElrath MJ, Tomaras GD, Goepfert P, Kalams S, Baden LR,
Lally M, Dolin R, Blattner W, Kalichman A, Figueroa JP, Pape J, Schechter M,
Defawe O, De Rosa SC, Montefiori DC, Nabel GJ, Corey L, Keefer MC; NIAID HIV
Vaccine Trials Network. A phase IIA randomized clinical trial of a multiclade
HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy
adults (HVTN204). PLoS One. 2011;6(8):e21225. doi: 10.1371/journal.pone.0021225.
Epub 2011 Aug 3. PMID: 21857901; PMCID: PMC3152265.

56: Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT,
Chakrabarti BK, Bailey MA, Gomez PL, Andrews CA, Moodie Z, Gu L, Stein JA, Nabel
GJ, Graham BS. A DNA vaccine for Ebola virus is safe and immunogenic in a phase
I clinical trial. Clin Vaccine Immunol. 2006 Nov;13(11):1267-77. doi:
10.1128/CVI.00162-06. Epub 2006 Sep 20. PMID: 16988008; PMCID: PMC1656552.

57: Gray GE, Metch B, Churchyard G, Mlisana K, Nchabeleng M, Allen M, Moodie Z,
Kublin J, Bekker LG; HVTN 503 team. Does participation in an HIV vaccine
efficacy trial affect risk behaviour in South Africa? Vaccine. 2013 Apr
12;31(16):2089-96. doi: 10.1016/j.vaccine.2013.01.031. Epub 2013 Jan 29. PMID:
23370155; PMCID: PMC3942784.

58: Horton H, Thomas EP, Stucky JA, Frank I, Moodie Z, Huang Y, Chiu YL,
McElrath MJ, De Rosa SC. Optimization and validation of an 8-color intracellular
cytokine staining (ICS) assay to quantify antigen-specific T cells induced by
vaccination. J Immunol Methods. 2007 May 31;323(1):39-54. doi:
10.1016/j.jim.2007.03.002. Epub 2007 Apr 3. PMID: 17451739; PMCID: PMC2683732.

59: Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Gu L,
Martin JE, Novik L, Chakrabarti BK, Butman BT, Gall JG, King CR, Andrews CA,
Sheets R, Gomez PL, Mascola JR, Nabel GJ, Graham BS; Vaccine Research Center 006
Study Team. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1
candidate vaccine delivered by a replication-defective recombinant adenovirus
vector. J Infect Dis. 2006 Dec 15;194(12):1638-49. doi: 10.1086/509258. Epub
2006 Nov 8. Erratum in: J Infect Dis. 2009 Oct 15;200(8):1352-3. PMID: 17109335;
PMCID: PMC2428071.

60: Laher F, Moodie Z, Cohen KW, Grunenberg N, Bekker LG, Allen M, Frahm N,
Yates NL, Morris L, Malahleha M, Mngadi K, Daniels B, Innes C, Saunders K, Grant
S, Yu C, Gilbert PB, Phogat S, DiazGranados CA, Koutsoukos M, Van Der Meeren O,
Bentley C, Mkhize NN, Pensiero MN, Mehra VL, Kublin JG, Corey L, Montefiori DC,
Gray GE, McElrath MJ, Tomaras GD. Safety and immune responses after a 12-month
booster in healthy HIV-uninfected adults in HVTN 100 in South Africa:
A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and
bivalent subtype C gp120/MF59 vaccines. PLoS Med. 2020 Feb 24;17(2):e1003038.
doi: 10.1371/journal.pmed.1003038. PMID: 32092060; PMCID: PMC7039414.

61: Moodie Z, Walsh SR, Laher F, Maganga L, Herce ME, Naidoo S, Hosseinipour MC,
Innes C, Bekker LG, Grunenberg N, Mann P, Yu C, deCamp AC, Miner MD, Yates NL,
Heptinstall J, Mkhize NN, Dintwe O, Frahm N, Cohen KW, Allen M, Hutter J, Wagner
R, Pantaleo G, McElrath MJ, Tomaras GD, Morris L, Montefiori DC, Andersen-Nissen
E, Gray GE, Gilbert PB, Kublin JG; NIAID HVTN 100 and HVTN 111 trial teams.
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as
compared with ALVAC priming: An analysis of two randomized controlled trials.
PLoS Med. 2020 May 22;17(5):e1003117. doi: 10.1371/journal.pmed.1003117. PMID:
32442195; PMCID: PMC7244095.

62: Huang Y, Huang Y, Moodie Z, Li S, Self S. Comparing and combining data
across multiple sources via integration of paired-sample data to correct for
measurement error. Stat Med. 2012 Dec 10;31(28):3748-59. doi: 10.1002/sim.5446.
Epub 2012 Jul 5. PMID: 22764070; PMCID: PMC4087038.

63: Follmann D, Duerr A, Tabet S, Gilbert P, Moodie Z, Fast P, Cardinali M, Self
S. Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from
a workshop. J Acquir Immune Defic Syndr. 2007 Jan 1;44(1):49-60. doi:
10.1097/01.qai.0000247227.22504.ce. PMID: 17075387; PMCID: PMC2682948.

64: Moodie FZ, Prentic RL. An adjustment to improve the bivariate survivor
function repaired NPMLE. Lifetime Data Anal. 2005 Sep;11(3):291-307. doi:
10.1007/s10985-005-2964-9. PMID: 16133881.